{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:52:20Z","timestamp":1790070740602,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00223-018-0444-y","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T15:01:04Z","timestamp":1529334064000},"page":"567-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis"],"prefix":"10.1007","volume":"103","author":[{"given":"Evelyne","family":"Gineyts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Bertholon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Pagnon-Minot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Borel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bonnelye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Croset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Suhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Truica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lamparella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Leitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Chapurlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Garnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11:411\u2013425","journal-title":"Nat Rev Cancer"},{"key":"444_CR2","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1007\/s00018-017-2646-2","volume":"74","author":"D Cui","year":"2017","unstructured":"Cui D, Huang Z, Liu Y, Ouyang G (2017) The multifaceted role of periostin in priming the tumor microenvironments for tumor progression. Cell Mol Life Sci 74:4287\u20134291","journal-title":"Cell Mol Life Sci"},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1038\/s41598-018-22340-7","volume":"8","author":"Y Nakazawa","year":"2018","unstructured":"Nakazawa Y, Taniyama Y, Sanada F, Morishita R, Nakamori S, Morimoto K, Yeung KT, Yang J (2018) Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep 8:4013","journal-title":"Sci Rep"},{"key":"444_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59\u201369","journal-title":"J Natl Cancer Inst"},{"key":"444_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","volume":"80","author":"R Coleman","year":"2011","unstructured":"Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A (2011) Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 80:411\u2013432","journal-title":"Crit Rev Oncol Hematol"},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.matbio.2014.04.007","volume":"37","author":"AY Liu","year":"2014","unstructured":"Liu AY, Zheng H, Ouyang G (2014) Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 37:150\u2013156","journal-title":"Matrix Biol"},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cmet.2014.09.005","volume":"20","author":"T Wu","year":"2014","unstructured":"Wu T, Wu S, Ouyang G (2014) Periostin: a new extracellular regulator of obesity-induced hepatosteatosis. Cell Metab 20:562\u2013564","journal-title":"Cell Metab"},{"key":"444_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fonc.2015.00224","volume":"5","author":"FA Venning","year":"2015","unstructured":"Venning FA, Wullkopf L, Erler JT (2015) Targeting ECM disrupts cancer progression. Front Oncol 5:224","journal-title":"Front Oncol"},{"key":"444_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1535-6108(04)00081-9","volume":"5","author":"S Bao","year":"2004","unstructured":"Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt\/PKB pathway. Cancer Cell 5:329\u2013339","journal-title":"Cancer Cell"},{"key":"444_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature10694","volume":"481","author":"I Malanchi","year":"2012","unstructured":"Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481:85\u201389","journal-title":"Nature"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00198-011-1892-7","volume":"23","author":"B Merle","year":"2012","unstructured":"Merle B, Garnero P (2012) The multiple facets of periostin in bone metabolism. Osteoporos Int 23:1199\u20131212","journal-title":"Osteoporos Int"},{"key":"444_CR12","doi-asserted-by":"publisher","first-page":"35939","DOI":"10.1074\/jbc.M109.060335","volume":"284","author":"N Bonnet","year":"2009","unstructured":"Bonnet N, Standley KN, Bianchi EN, Stadelmann V, Foti M, Conway SJ, Ferrari SL (2009) The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem 284:35939\u201335950","journal-title":"J Biol Chem"},{"key":"444_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bone.2014.10.011","volume":"71","author":"M Gerbaix","year":"2015","unstructured":"Gerbaix M, Vico L, Ferrari SL, Bonnet N (2015) Periostin expression contributes to cortical bone loss during unloading. Bone 71:94\u2013100","journal-title":"Bone"},{"key":"444_CR14","doi-asserted-by":"publisher","first-page":"15048","DOI":"10.1073\/pnas.1203085109","volume":"109","author":"N Bonnet","year":"2012","unstructured":"Bonnet N, Conway SJ, Ferrari SL (2012) Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci USA 109:15048\u201315053","journal-title":"Proc Natl Acad Sci USA"},{"key":"444_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1200\/JCO.2002.20.6.1467","volume":"20","author":"A Lipton","year":"2002","unstructured":"Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J (2002) Elevated serum Her-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467\u20131472","journal-title":"J Clin Oncol"},{"key":"444_CR16","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1210\/jc.2013-3893","volume":"99","author":"JC Rousseau","year":"2014","unstructured":"Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P (2014) Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab 99:2533\u20132539","journal-title":"J Clin Endocrinol Metab"},{"key":"444_CR17","doi-asserted-by":"publisher","first-page":"11131","DOI":"10.1128\/MCB.25.24.11131-11144.2005","volume":"25","author":"H Rios","year":"2005","unstructured":"Rios H, Koushik SV, Wang H, Wang J, Zhou HM, Lindsley A, Rogers R, Chen Z, Maeda M, Kruzynska-Frejtag A, Feng JQ, Conway SJ (2005) Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25:11131\u201311144","journal-title":"Mol Cell Biol"},{"key":"444_CR18","doi-asserted-by":"publisher","first-page":"17991","DOI":"10.1074\/jbc.M708029200","volume":"283","author":"DL Coutu","year":"2008","unstructured":"Coutu DL, Wu JH, Monette A, Rivard GE, Blostein MD, Galipeau J (2008) Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J Biol Chem 283:17991\u201318001","journal-title":"J Biol Chem"},{"key":"444_CR19","doi-asserted-by":"publisher","first-page":"e0135374","DOI":"10.1371\/journal.pone.0135374","volume":"10","author":"DS Annis","year":"2015","unstructured":"Annis DS, Ma H, Balas DM, Kumfer KT, Sandbo N, Potts GK, Coon JJ, Mosher DF (2015) Absence of vitamin K-dependent gamma-carboxylation in human periostin extracted from fibrotic lung or secreted from a cell line engineered to optimize gamma-carboxylation. PLoS ONE 10:e0135374","journal-title":"PLoS ONE"},{"key":"444_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-010-9391-y","volume":"87","author":"S Contie","year":"2010","unstructured":"Contie S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Clezardin P, Garnero P (2010) Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int 87:341\u2013350","journal-title":"Calcif Tissue Int"},{"key":"444_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ijc.25591","volume":"128","author":"S Contie","year":"2011","unstructured":"Contie S, Voorzanger-Rousselot N, Litvin J, Clezardin P, Garnero P (2011) Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer 128:352\u2013360","journal-title":"Int J Cancer"},{"key":"444_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.joca.2015.05.015","volume":"23","author":"JC Rousseau","year":"2015","unstructured":"Rousseau JC, Sornay-Rendu E, Bertholon C, Garnero P, Chapurlat R (2015) Serum periostin is associated with prevalent knee osteoarthritis and disease incidence\/progression in women: the OFELY study. Osteoarthr Cartil 23:1736\u20131742","journal-title":"Osteoarthr Cartil"},{"key":"444_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1021899904332","volume":"77","author":"H Sasaki","year":"2003","unstructured":"Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A (2003) Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 77:245\u2013252","journal-title":"Breast Cancer Res Treat"},{"key":"444_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/prep.1995.1040","volume":"6","author":"T Sugiura","year":"1995","unstructured":"Sugiura T, Takamatsu H, Kudo A, Amann E (1995) Expression and characterization of murine osteoblast-specific factor 2 (OSF-2) in a baculovirus expression system. Protein Expr Purif 6:305\u2013311","journal-title":"Protein Expr Purif"},{"key":"444_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1515\/hsz-2013-0134","volume":"394","author":"M Novinec","year":"2013","unstructured":"Novinec M, Lenarcic B (2013) Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem 394:1163\u20131179","journal-title":"Biol Chem"},{"key":"444_CR26","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/jbmr.3136","volume":"32","author":"N Bonnet","year":"2017","unstructured":"Bonnet N, Brun J, Rousseau JC, Duong LT, Ferrari SL (2017) Cathepsin K controls cortical bone formation by degrading periostin. J Bone Miner Res 32:1432\u20131441","journal-title":"J Bone Miner Res"},{"key":"444_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00223-017-0302-3","volume":"101","author":"P Garnero","year":"2017","unstructured":"Garnero P, Bonnet N, Ferrari SL (2017) Development of a new immunoassay for human cathepsin K-generated periostin fragments as a serum biomarker for cortical bone. Calcif Tissue Int 101:501\u2013509","journal-title":"Calcif Tissue Int"},{"key":"444_CR28","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4049\/jimmunol.1102843","volume":"188","author":"YH Hsu","year":"2012","unstructured":"Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS (2012) Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol 188:1981\u20131991","journal-title":"J Immunol"},{"key":"444_CR29","first-page":"5386","volume":"57","author":"AJ Littlewood-Evans","year":"1997","unstructured":"Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, Inaoka T, Sloane J, Evans DB, Gallagher JA (1997) The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386\u20135390","journal-title":"Cancer Res"},{"key":"444_CR30","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/1535-7163.MCT-14-0253","volume":"13","author":"LT Duong","year":"2014","unstructured":"Duong LT, Wesolowski GA, Leung P, Oballa R, Pickarski M (2014) Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol Cancer Ther 13:2898\u20132909","journal-title":"Mol Cancer Ther"},{"key":"444_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCGENETICS.112.964452","volume":"6","author":"C Stegemann","year":"2013","unstructured":"Stegemann C, Didangelos A, Barallobre-Barreiro J, Langley SR, Mandal K, Jahangiri M, Mayr M (2013) Proteomic identification of matrix metalloproteinase substrates in the human vasculature. Circ Cardiovasc Genet 6:106\u2013117","journal-title":"Circ Cardiovasc Genet"},{"key":"444_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bone.2003.08.011","volume":"34","author":"P Hou","year":"2004","unstructured":"Hou P, Troen T, Ovejero MC, Kirkegaard T, Andersen TL, Byrjalsen I, Ferreras M, Sato T, Shapiro SD, Foged NT, Delaisse JM (2004) Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 34:37\u201347","journal-title":"Bone"},{"key":"444_CR33","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","volume":"67","author":"C Gall Le","year":"2007","unstructured":"Le Gall C, Bellahcene A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clezardin P (2007) A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67:9894\u20139902","journal-title":"Cancer Res"},{"key":"444_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1479-5876-9-109","volume":"9","author":"B Chen","year":"2011","unstructured":"Chen B, Platt MO (2011) Multiplex zymography captures stage-specific activity profiles of cathepsins K, L, and S in human breast, lung, and cervical cancer. J Transl Med 9:109","journal-title":"J Transl Med"},{"key":"444_CR35","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1158\/1078-0432.CCR-08-0732","volume":"14","author":"CG Kleer","year":"2008","unstructured":"Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K (2008) Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 14:5357\u20135367","journal-title":"Clin Cancer Res"},{"key":"444_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.biopha.2007.07.001","volume":"62","author":"FM Tumminello","year":"2008","unstructured":"Tumminello FM, Flandina C, Crescimanno M, Leto G (2008) Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomed Pharmacother 62:130\u2013135","journal-title":"Biomed Pharmacother"},{"key":"444_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/jbmr.5650090215","volume":"9","author":"P Garnero","year":"1994","unstructured":"Garnero P, Grimaux M, Seguin P, Delmas PD (1994) Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9:255\u2013264","journal-title":"J Bone Miner Res"},{"key":"444_CR38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1074\/mcp.M114.047621","volume":"14","author":"DS Rehder","year":"2015","unstructured":"Rehder DS, Gundberg CM, Booth SL, Borges CR (2015) Gamma-carboxylation and fragmentation of osteocalcin in human serum defined by mass spectrometry. Mol Cell Proteom 14:1546\u20131555","journal-title":"Mol Cell Proteom"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-018-0444-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0444-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0444-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T23:17:39Z","timestamp":1560813459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-018-0444-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1007\/s00223-018-0444-y","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"24 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Evelyne Gineyts, Nicolas Bonnet, Cindy Bertholon, Marjorie Millet, Aur\u00e9lie Pagnon-Minot, Olivier Borel, Sandra Geraci, Edith Bonnelye, Martine Croset, Ali Suhail, Cristina Truica, Nicholas Lamparella, Kim Leitzel, Daniel Hartmann, Roland Chapurlat, Allan Lipton, Patrick Garnero, Serge Ferrari, Philippe Cl\u00e9zardin, and Jean-Charles Rousseau declare that they have no conflict of interest with the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided written informed consent. Animal studies were approved by local ethical committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}